Main Uses and Therapeutic Applications

Korea Levosulpiride is a medication primarily classified as a prokinetic agent and an antipsychotic, though its clinical application in many regions focuses on the management of gastrointestinal motility disorders. It works by acting as a selective antagonist of dopamine D2 receptors.

Functional Gastrointestinal Disorders

The most common application for this medication is the treatment of functional dyspepsia. This condition involves chronic or recurrent discomfort in the upper abdomen that does not have an obvious structural cause. The medication helps alleviate symptoms such as:

• Postprandial fullness: A sensation that food remains in the stomach for an unnaturally long period after eating.
• Early satiety: Feeling full shortly after beginning a meal, preventing the consumption of a normal portion.
• Epigastric bloating: Swelling or pressure in the upper abdominal region.
• Nausea and vomiting: Reducing the urge to vomit associated with slowed gastric emptying.

Gastroparesis

Korea Levosulpiride is utilized to manage gastroparesis, a condition characterized by delayed gastric emptying. By enhancing the frequency and force of stomach contractions, the medication facilitates the movement of food from the stomach into the small intestine. This is particularly relevant for individuals experiencing gastric stasis related to metabolic conditions or idiopathic causes.

Mechanisms of Benefit

The benefits of Korea Levosulpiride stem from its ability to modulate the enteric nervous system and the central nervous system.

Improved Gastric Motility

By blocking dopamine receptors that normally inhibit the release of acetylcholine, the medication increases the tone of the lower esophageal sphincter and coordinates the movement of the upper digestive tract. This prokinetic effect reduces the time it takes for the stomach to empty its contents.

Somatization and Mood-Related Gastrointestinal Symptoms

Due to its activity on dopamine receptors in the brain, the medication may also be used to address physical symptoms that are exacerbated by psychological factors. In lower doses, it can help manage symptoms of anxiety or somatoform disorders that manifest as digestive distress, providing a dual approach to patients whose gastrointestinal issues are linked to the autonomic nervous system.

Regulatory References

1. Malta Medicines Authority guidance on Dislep

Eligibility Map: Who can and cannot use Levosulpiride — official regulatory information

The eligibility profile for Levosulpiride is strictly defined by regulatory documents, listing groups who must not use the medicine (Contraindications) and groups requiring restricted use.

This structure reflects the drug's absolute contraindications concerning its hormonal and neurological activity, combined with constraints related to organ function and patient age, as specified in regulatory prescribing information.

The interaction profile for Levosulpiride is defined by several clinically significant pharmacodynamic and pharmacokinetic patterns documented in regulatory labeling.

Formal Interaction Restrictions

The co-administration of Levodopa is formally contraindicated because Levosulpiride acts as a dopamine antagonist, leading to competitive antagonism that reduces the efficacy of Levodopa. Alcohol and other CNS Depressants (Central Nervous System depressants) are documented to cause an additive sedative effect and must be avoided. Further restrictions involve agents that affect heart rhythm: concurrent use with QT-prolonging agents or medicines that induce electrolyte abnormalities (e.g., certain diuretics causing hypokalemia) increases the risk of documented cardiac arrhythmias.

Altered Drug Exposure and Timing

Pharmacokinetic interactions require careful timing with certain co-administered substances. Sucralfate and Antacids containing aluminum or magnesium are documented to reduce the absorption of Levosulpiride. To prevent this alteration in drug exposure, regulatory requirements mandate that Levosulpiride must be administered with a minimum 2-hour separation from these agents.

Antagonistic Effects and Population Notes

Levosulpiride's gastroprokinetic effect may be antagonized by specific drug classes, including Anticholinergic Agents, Narcotics, and some Analgesic Drugs. Additionally, co-administration with Antihypertensive Agents may enhance their hypotensive effects. Precautions are also noted for patients with impaired renal function, as drug clearance is affected, potentially altering exposure parameters.

How Korea Levosulpiride Works

The mechanism of action for Levosulpiride involves key modulations within both the central and peripheral nervous systems, primarily through its effects on dopamine and serotonin signaling pathways.

Central Dopamine Receptor Antagonism

Levosulpiride acts as a selective antagonist of the Dopamine D2 receptors, predominantly blocking them in specific brain pathways. This engagement with D2 receptors in the central nervous system helps to regulate dysregulated processes associated with heightened physiological responses, resulting in the modulation of neural signaling patterns.

Peripheral Prokinetic Activity via D2 and 5-HT4 Modulation

In the gastrointestinal system, Levosulpiride continues to block Dopamine D2 receptors on enteric nerves and muscle. D2 receptor inhibition removes a normal inhibitory brake on the release of acetylcholine, a neurotransmitter. This action, combined with a mild agonist effect on the Serotonin 5-HT4 receptors, initiates signaling sequences that enhance the force and coordination of gut contractions. This sequence of events modulates the intrinsic rhythmicity and strength of gastrointestinal smooth muscle contractions.

Official Administration Guidelines

Levosulpiride is administered according to specific regimens that dictate the form, route, and timing of the dose. It is available for oral use (tablets, sustained-release tablets, and oral drops) and for parenteral use (intravenous/intramuscular injection).

For pediatric patients, the use of levosulpiride is not indicated. If a sustained-release dose is missed, instructions specify skipping the dose and not taking two doses to compensate. These instructions define the standardized approach for the drug's proper use.

Research evidence / Overview of Studies for Korea Levosulpiride

Research into levosulpiride has focused primarily on the digestive tract, and research has explored its role in conditions involving certain symptoms that interfere with daily functioning. The information below summarizes the types of studies conducted and the patterns described by researchers, but it is not intended as clinical advice or a guarantee of personal outcomes.

Evidence for Functional Dyspepsia and Upper GI Symptoms

Clinical research has primarily explored the study of levosulpiride in adults who have conditions characterized by fluctuating or episodic manifestations in the upper digestive area, known as functional dyspepsia. This area of study is supported by a number of short-term randomized controlled trials (RCTs) and systematic reviews.

These studies described changes measured during the study period in global symptom scores and individual symptom intensity. Additionally, research examined physiological measures, like the speed of gastric emptying. Comparative trials and meta-analyses described patterns of change in symptom scores that were measured over the typical 4-week study period, including comparisons against placebo. The research mainly focused on the dysmotility-like subtype of functional dyspepsia, and certainty regarding long-term effects remains low.

Evidence for Diabetic Gastroparesis

Research was studied for conditions involving delayed gastric emptying associated with diabetes, known as diabetic gastroparesis. Studies explored the use of the medicine in this comorbidity-defined group through trials that assessed short-term symptom changes. These trials monitored outcomes related to physical discomfort and assessed objective measures like the rate of stomach emptying (gastric motility).

Sample sizes were modest in many of the key trials, and data show patterns related to measured changes in both symptoms and gastric emptying in these specific study populations. In some longer studies (up to 6 months), changes in HbA1c was observed in some studies in certain groups of insulin-treated patients. However, there is limited information on what findings may indicate about symptoms or metabolic control over many months or years.

Research Gaps and Remaining Uncertainty

One key limitation is that follow-up durations were limited across many of the central efficacy studies, meaning there is limited information for long-term outcomes. Furthermore, sample sizes were modest in some of the specific research conducted, and subgroup findings for patients outside the primary trial populations remain uncertain.

Key Studies & References

1. Summary of Product Characteristics (SPC) for Dislep (Levosulpiride)
2. WHO ATC Classification System: N05AL07 Levosulpiride

Common questions about Korea Levosulpiride (FAQ)

Q: Is Korea Levosulpiride the same kind of drug as regular sulpiride?

Official sources describe levosulpiride as the active S-(-)-enantiomer, which means it is one specific, active form of the chemical compound sulpiride. It is the form primarily developed and used for its effects on the digestive system.

Q: What is the purpose of levosulpiride in managing functional dyspepsia?

In the context of functional dyspepsia (a condition causing chronic upper stomach symptoms), official studies describe its purpose as a prokinetic agent. This means it is used to enhance the force and coordination of the muscles in the upper gastrointestinal tract to relieve associated symptoms. Research has focused mainly on its action in the dysmotility-like subtype of the condition.

Q: What research evidence exists supporting the use of Korea Levosulpiride?

Research has primarily explored its use in short-term studies for certain upper digestive conditions, notably functional dyspepsia and diabetic gastroparesis. These clinical trials measure outcomes by assessing changes in symptom severity and objective measures of gastric emptying speed.

Q: What is the general expectation for improvement when using this medication?

Clinical studies that examine the effects of levosulpiride typically assess changes in global and individual symptom scores over a study period of about 4 weeks. Official documents note that information for long-term outcomes extending beyond these short-term studies remains limited.

Q: Can Korea Levosulpiride be taken with other medicines that affect the stomach?

Official documents describe that antacids containing aluminum or magnesium, as well as sucralfate, can reduce the body's absorption of levosulpiride. For this reason, regulatory documents typically state that levosulpiride should be administered with a minimum 2-hour separation from these agents. Official guidance is not consistently documented for all other stomach medicines, such as proton pump inhibitors (PPIs).

Q: Does taking Korea Levosulpiride with food change how well it works?

The oral form of the medicine is officially directed to be taken at least 20 minutes before meals. This timing is specified because food intake may alter the absorption of the medicine, which could affect the concentration of the drug in the body.

Q: Can Korea Levosulpiride cause mood swings or changes in behavior?

The medicine is chemically classified as an atypical antipsychotic and works by acting on the central nervous system. Officially reported side effects related to the nervous system include drowsiness (somnolence) and fatigue. Specific mood swings or aggressive behavioral changes are not consistently documented across common frequency lists in official materials.

Q: What should a patient do if they experience a severe headache while on the medication?

Headache is listed in official documentation as a potential documented adverse event. For this or any other symptom causing serious concern, official safety guidance describes the protocol of consulting with a healthcare professional.

Q: Is Korea Levosulpiride primarily used for stomach issues or mood concerns?

While the drug is classified as an atypical antipsychotic based on its chemical structure, official prescribing documents primarily list its approved use for functional gastrointestinal disorders, such as functional dyspepsia. Its primary clinical application is related to enhancing gastrointestinal movement.

Q: Can Korea Levosulpiride cause changes in sleep patterns?

Official side effect documentation lists drowsiness (somnolence) and fatigue as common potential adverse reactions, reflecting its action on the nervous system. Specific changes in sleep patterns, such as insomnia, are not consistently documented across common frequency categories in regulatory documents.

Q: Is it common for people to feel dizzy after taking Korea Levosulpiride?

Some regulatory-related patient information notes that the medicine can cause dizziness, along with drowsiness or numbness. These effects are related to the drug's activity in the central nervous system.

Q: Are there any specific foods or drinks to avoid when taking this medication?

Official warnings state that alcohol and other Central Nervous System (CNS) depressants must be avoided due to an increased risk of sedation. No specific non-alcoholic food or drink restrictions are consistently noted in regulatory documentation, outside of the required separation from antacids and sucralfate.

Q: What happens if a dose of Korea Levosulpiride is missed?

If a dose of levosulpiride is missed, regulatory information advises skipping the missed dose and continuing with the next scheduled dose. Official documentation advises patients not to take two doses at the same time in an attempt to compensate for the missed one.

Q: Are there warnings about driving or operating machinery while taking this medicine?

Regulatory warnings advise caution regarding activities that require mental focus, such as driving or operating machinery, as the medicine can cause drowsiness or dizziness.

Q: Is there a link between levosulpiride and low blood pressure?

Official safety information documents that co-administration with antihypertensive agents (drugs used to lower blood pressure) may enhance the hypotensive effects of those medicines. The drug is not typically listed as causing significant changes in blood pressure on its own.

Q: How quickly does the active ingredient leave the body?

Official information describes the time it takes for the active ingredient to leave the body as the elimination half-life. Pharmacokinetic studies report this as typically ranging from 6 to 19 hours after oral administration, depending on the specific dosage and formulation.

Q: Is it possible for Korea Levosulpiride to cause allergic reactions?

Regulatory documentation lists known hypersensitivity to Levosulpiride as an absolute contraindication. This means that the medicine is contraindicated in individuals with a known allergic reaction to the drug.

Q: Can Korea Levosulpiride impact fertility?

The medicine is known to potentially cause elevated levels of the hormone prolactin (hyperprolactinemia). Official documents list related effects such as irregular or absent menstruation, which are connected to the endocrine and reproductive systems.

Q: What regulatory bodies have approved levosulpiride for use in their regions?

Levosulpiride is highly utilized in South Korea and parts of Europe, and it is categorized by the World Health Organization (WHO). It is officially reviewed and regulated by national authorities like the Rwanda FDA and Malta Medicines Authority, among others, based on regional regulatory processes.

Levosulpiride tablets must be stored according to regulatory labeling to maintain their 36-month shelf life. Storage must be at a temperature not exceeding 30 C (86 F). The product must be protected from moisture and direct sunlight and should not be frozen. Keep the container tightly closed and always store the medicine out of the reach of children. Unused or expired Levosulpiride must be disposed of via community drug take-back programs as the preferred method. If take-back is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (like coffee grounds), sealed in a bag, and then placed in the trash. Do not flush the medicine down the toilet or sink unless specific instructions on the label advise otherwise.